萊美藥業(300006.SZ)擬1200萬元轉讓萊美金鼠70%股權
格隆匯1月15日丨萊美藥業(300006.SZ)公佈,為了加快推進資產處置進度,進一步聚焦優勢細分領域,公司於2021年1月15日召開的第五屆董事會第十一次會議、第五屆監事會第八次會議分別審議通過了《關於轉讓重慶萊美金鼠中藥飲片有限公司股權的議案》,同意公司全資子公司重慶市萊美醫藥有限公司(以下簡稱“萊美醫藥”)與重慶芝臣科技有限責任公司(以下簡稱“芝臣科技”)簽署《股權轉讓協議》,同意萊美醫藥將其持有重慶萊美金鼠中藥飲片有限公司(以下簡稱“萊美金鼠”、“目標公司”)70%股權以人民幣1200萬元轉讓給芝臣科技,萊美金鼠其他少數股東同意本次股權轉讓事項並出具了放棄優先購買權聲明。本次股權轉讓交易完成後,萊美金鼠將不再納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.